Aisling Capital
Venture capitalNew York · Seed–Series C · 16 people tracked
Also known as AISLING CAPITAL LLC · AISLING CAPITAL MANAGEMENT LP
Investment thesis
Aisling Capital invests in companies developing and commercializing important, innovative healthcare products, services, and technologies. Since 2000, the firm has built a track record of deploying and returning capital, managing $1.8 billion in assets. Its portfolio spans biotechnology and therapeutics companies advancing novel treatments across areas such as cell therapies, rare diseases, and psychedelics-based medicine.
Source: firm website, verified Aug 25, 2026.
Team · 16 people
from the firm's website & public directories
What they invest in
from 85 of 122 portfolio companiesBiotech ×66Healthtech ×65Medical Devices ×23Wellness & Fitness ×7Consumer ×6Digital Health ×5Advanced Manufacturing ×4AI & Machine Learning ×4
HQs:United States×53Vietnam×2Canada×1Switzerland×1Denmark×1Italy×1
Who they back
founder profiles across 23 portfolio companiesFounding team size:solo founder×122 founders×83 founders×3
Investments · 122 tracked
founders shown can be your intro pathBy year:2025 · 22024 · 22021 · 12020 · 12019 · 12018 · 12017 · 22016 · 32015 · 22014 · 42012 · 221 dated
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Markus Warmuth(M.D., Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)John Castle(Ph.D., Chief Data and Information Officer)Filip Janku(M.D., Ph.D., Chief Medical Officer)Phil Nickson(Ph.D., J.D., Chief Business and Legal Officer)Magnus Walter(DPhil, Chief Technology Officer)
Co-investorsNew Enterprise Associates (NEA)Versant VenturesHBM PartnersAmzak HealthAvoro Capital AdvisorsGV (Google Ventures)+1 more
HealthtechOrlando, US
Randy W Frey(Director)Alan B Connaughton(Executive Officer)Amy R Brooks(Executive Officer)Peter J Mariani(Executive Officer)Keith H Edwards(Executive Officer)Ronald D Goldrich(Executive Officer)
Board seatSteven ElmsJosh Bilenker· per SEC Form D
Co-investorsVersant Venture AIV Holdings
Marker Therapeutics develops novel T cell therapies, including adoptive T cell therapy approaches, for clinical applications in oncology and other diseases with high unmet need.
BiotechHealthtechHouston, US
Juan Vera(Executive Officer, Director)Dr. Vera(Co-founder)Glynn Wilson(Executive Officer, Director)John Bonfiglio(Executive Officer, Director)
BoardJohn Wilson(Director)
Board seatSteven Elms· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)
Co-investorsAPERTURE Venture PartnersF-Prime CapitalForesite CapitalRA CapitalSofinnova VenturesSofinnova Venture Partners+1 more
ADMA Biologics develops and manufactures specialty plasma-derived biologic products, including immune globulin therapies, for immune-compromised patients and others at risk of certain infections.
Advanced ManufacturingBiotechHealthtechHackensack, US
Adam S Grossman(Executive Officer, Director)Jerrold B Grossman(Director)
BoardDov Goldstein(Director)Bryant E Fong(Director)Steven A Elms(Director)Eric I Richman(Director)
Co-investorsEight Roads VenturesF-Prime CapitalForesite CapitalPremji InvestRA CapitalRed Tree Venture+1 more
BiotechRedwood City, US
Thomas Butler(Executive Officer, Director)Ramses Erdtmann(Director, Executive Officer)
Compass Pathways develops psychedelic-based treatments for mental health conditions, aiming to create a new clinical standard for patients underserved by current care.
BiotechDigital HealthMental Health
Co-investorsAble PartnersCatalio Capital Management, LPNoeticOMX VenturesVivo CapitalJam Fund
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey Aronin(Director)Jeffrey M. Dayno, M.D.(President and Chief Executive Officer)Patrick Morris(Secretary and Treasurer)Robert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)
BoardAaron Royston(Director)in
Co-investorsParagon Biosciences LLCValor Equity PartnersvenBio PartnersVivo Capital
Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.
BiotechHealthtechMedical DevicesNew Brunswick, US
Joaquin Duatoin
Co-investorsAtlas VentureNaviMed CapitalPortland Seed FundSPRINGROCK VENTURESThe Column GroupvenBio Partners
Nuvation Bio is a global oncology company developing and commercializing novel therapies for difficult-to-treat cancers, targeting indications where conventional treatments have failed.
BiotechHealthtechNew York, US
David Hung(Founder, President & Chief Executive Officer)
Co-investorsDecheng CapitalEcoR1 CapitalVertex Ventures ChinaOmega Funds
Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
BiotechHealthtechMilpitas, US
Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)
BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)
Co-investorsCanaan PartnersJJDCLilly VenturesStarfish Ventures
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)
BoardKristina Burow(Director)inAmir Nashat(Director)inKatrine Bosley(Director)Michael Gilman(Director)
Co-investorsARCH Venture PartnersEcoR1 CapitalPolaris Partners
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Javier Szwarcberg(Executive Officer, Director)Samir Gharib(Executive Officer)RICHARD KING(Executive Officer, Director)
BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in
Co-investorsHealthCapRiverVest Venture PartnersAbingworthNorwest Venture PartnersOrbiMed
Spyre Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunology, aiming for more complete disease control, greater durability, and simpler treatment.
BiotechHealthtech
Co-investorsAccess Biotechnology
Earlens makes a hearing aid that vibrates the eardrum directly rather than using speakers to amplify sound, allowing amplification across a broad audible frequency range including higher frequencies for speech understanding.
HardwareHealthtechMedical DevicesMenlo Park, US
Rodney Perkins, M.D.(Director)William M. Facteau(Executive Officer, Director)Bernard Shay(Executive Officer)Phil Lyons(Executive Officer)Brent Edwards(Executive Officer)Greg Koskowich(Executive Officer)
Board seatSteven Elms· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)Windham Capital PartnersLightstone VenturesSightLine Partners
BiotechCambridge, US
Dhvanit I Shah(Chief Executive Officer of the Issuer)David Kirske(Executive Officer)Adam Craig(Executive Officer, Director)
BoardGeoff Meyerson(Director)Raymond Kelleher(Director)
Board seatEric Aguiar· per SEC Form D · filed Oct 2024
Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Sean George(Executive Officer, Director)Randal Scott(Executive Officer, Director)Shelly Guyer(Executive Officer)Lee Bendekgey(Executive Officer)Geoffrey Crouse(Director)
Board seatEric Aguiar· per SEC Form D · $6M raise · filed Jun 2017
Co-investorsCivilization Ventures Management, LlcDecheng CapitalFifty YearsManta Ray VenturesOberland CapitalPrefix Capital+1 more
Summus Global provides doctor-led clinical navigation and virtual access to specialists across 120+ medical specialties, offering members personalized guidance, second opinions, in-network recommendations, and condition-specific support programs.
Digital HealthHealthtechWellness & FitnessNew York, US
Julian Flannery(Executive Officer, Director)
BoardRick Buhrman(Director)Dennis Purcell(Executive Officer)inAftab Kherani(Director)Scott Harrison(Director)
Board seatAyman Sabi· per SEC Form D · $16M raise · filed Apr 2021
Co-investorsOutsidersTeamworthy Ventures
Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures.
AI & Machine LearningHealthtechMedical DevicesRoboticsMorrisville, US
Anthony Fernando(Executive Officer)Todd M Pope(Executive Officer, Director)Joseph P Slattery(Executive Officer)Todd M. Pope(Executive Officer, Director)James J. Martin(Executive Officer)Charles J. Filipi(Executive Officer, Director)
Board seatAftab Kherani· per SEC Form D
Co-investorsSV Health InvestorsQuaker BioVenturesSV Life Sciences
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in
BoardKristina Burow(Director)inAli Satvat(Director)David Schenkein(Director)in
Board seatSteven ElmsAftab Kherani· per SEC Form D
Co-investorsARCH Venture PartnersOrbiMedCasdin CapitalFidelity InvestmentsGV (Google Ventures)Rock Springs Capital+1 more
Advion Interchim Scientific develops mass spectrometry instruments, including compact chemist-centric mass spectrometers, nanoelectrospray ionization sources, and ICP-MS systems for elemental analysis.
BiotechDeep TechHardwareIthaca, US
Jamey Jones(Chief Executive Officer)John G. Freund(Director)John D. Henion(Director)J. Kenneth Walker(Director)Zachary Shulman(Director)Francis H. Zenie(Director)
Co-investorsGefinor Capital
Agile Therapeutics develops and markets contraceptive and women's health products using its proprietary Skinfusion® transdermal technology platform.
BiotechFemTechHealthtechPrinceton, US
Katie MacFarlane(Executive Officer)Scott M. Coiante(Executive Officer)Al Altomari(Executive Officer, Director)Elizabeth Garner(Executive Officer)
BoardKaren Hong(Director)Abhijeet Lele(Director)
Co-investorsKaiser Permanente Ventures
Co-investorsLongitude Capital
Ajax is a global investment firm that partners with industry leaders to build and scale healthcare businesses.
Healthtech
Co-investorsLYZZ CapitalRiverVest Venture Partners
Pfizer discovers, develops, manufactures, and distributes pharmaceutical medicines and vaccines across therapeutic areas including oncology, cardiology, immunology, and infectious diseases.
BiotechHealthtechMedical DevicesNew York, US
Charles Pfizer
Co-investorsAndera PartnersRho Capital PartnersRho VenturesRiverVest Venture PartnersVenrockNew Enterprise Associates (NEA)
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)Tamra Adams(Executive Officer)Abel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAltium CapitalAvego BioScience CapitalPontifax Venture Capital
Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.
Biotech
Juan Jaen(Founder)in
Co-investorsDecheng CapitalDroia VenturesEcoR1 CapitalForesite CapitalSLVCSofinnova Ventures+2 more
A biopharmaceutical company connected to the B-FLEXION group, which spans asset management businesses and direct holdings in operating companies built over roughly two decades.
Biotech
Co-investorsLAVLilly Asia VenturesQuan Capital
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)James Healy(Director)Grethe Rasmussen(Executive Officer)Harald Rau(Executive Officer)Rafa?le Tordjman(Director)Martin Olin(Director)
Co-investorsVivo CapitalAvoro Capital AdvisorsForesite CapitalRA CapitalSofinnova Ventures
BiotechRedwood City, US
William Robinson(Director)Lawrence Steinman(Director)Tito Serafini(Executive Officer, Director)
BoardBrian Atwood(Director)Franklin Berger(Director)
Co-investorsEcoR1 CapitalMission Bay CapitalMission Biocapital
Co-investorsSofinnova Ventures
Co-investorsBrace Pharma
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.
BiotechHealthtech
Vlad Coric(Chairman & Chief Executive Officer)
Co-investorsAPERTURE Venture PartnersConnecticut InnovationsOUP (Osage University Partners)
Biopharmaceutical developer of tumor-selective PARP inhibitor cancer therapies, acquired by Sanofi-aventis in 2009.
Co-investorsAsset Management CompanyCanaan PartnersKleiner PerkinsSPRINGROCK VENTURESVantagePoint Capital PartnersDomain Associates
BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.
BiotechHealthtech
Co-investorsAmzak HealthEcoR1 CapitalFrazier Life SciencesHEALTHCARE ROYALTY PARTNERSLongwood FundSequoia Capital
BridgeBio Oncology develops cancer therapies targeting tumors driven by RAS and PI3Kα signaling, using RAS signaling biology to design drugs that inhibit RAS-driven PI3K activation and a range of KRAS mutants in both their active (ON) and inactive (OFF) states.
BiotechHealthtech
CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases.
BiotechHealthtech
Kenneth A. Stauderman(Co-founder)Gonul Velicelebi(Co-founder)Stephen Bardin(Chief Financial Officer)Sudarshan Hebbar(Chief Medical Officer)Andrew Cunningham(Executive)
BoardEric W. Roberts(Chairman of the Board)
Co-investorsSanderling Ventures
Catalent is a global Contract Development and Manufacturing Organization (CDMO) that helps pharma, biotech, and self-care companies develop, manufacture, and deliver drug products and consumer health solutions.
Advanced ManufacturingBiotechHealthtechSomerset, US
John R. Chiminski(Executive Officer, Director)Wetteny Joseph(Executive Officer)Donald E. Morel Jr.(Director)Peter Zippelius(Director)
BoardJack L. Stahl(Director)Madhavan Balachandran(Director)
Co-investorsHavencrest Capital ManagementLeonard GreenBlackstone
Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.
BiotechHealthtechMedical Devices
Co-investorsAlta PartnersAsset Management CompanyCanaan PartnersFrazier Life SciencesSanderling Ventures
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)Kevin Forrest(Executive Officer)Dirk Thye(Executive Officer)Ken Bartizal(Executive Officer)Paul Daruwala(Executive Officer)
Co-investors5AM VenturesBain Capital Life SciencesFrazier Life SciencesRA CapitalVivo CapitalCanaan Partners+1 more
Patrick Mahaffy(Founder)in
Co-investorsNew Enterprise Associates (NEA)Ridgeback Capital
Colorescience is a professional skincare brand that develops mineral-based sun protection (SPF), skincare, and color correction products, originally created for post-procedure skin and marketed for all ages and skin types.
ConsumerDirect to ConsumerHealthtechWellness & FitnessCarlsbad, US
Stephen Loomis(Executive Officer)Mary Fisher(Executive Officer, Director)Theodore Ebel(Executive Officer)Lynelle Lynch(Director)Howard D. Palefsky(Director)Brian H. Dovey(Director)
Co-investors1315 CapitalDomain AssociatesHealthCare Ventures, LLCLongwood FundRoundTable Healthcare PartnersSplit Rock Partners
CoolSculpting offers FDA-cleared body-contouring procedures that use controlled cooling to reduce visible fat bulges in areas such as the chin, abdomen, thighs, and flanks, along with the CoolTone device for muscle strengthening and toning.
HealthtechMedical DevicesWellness & Fitness
Co-investorsLightstone Ventures
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalLumira VenturesMenlo Ventures+5 more
IQVIA (via the quintiles.com domain) provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution.
AI & Machine LearningBiotechHealthtech
Co-investorsAccess Venture Partners
Cynapsus is a specialty central nervous system pharmaceutical company developing a fast-acting, sublingual thin film for on-demand management of OFF episodes in Parkinson's disease patients.
BiotechHealthtechToronto, CA
Anthony Giovinazzo(Executive Officer, Director)Andrew Williams(Executive Officer)Thierry Bilbault(Executive Officer)Nathan Bryson(Executive Officer)
BoardIlan Oren(Director)Tomer Gold(Director)
HealthtechMenlo Park, US
THOMAS G. WIGGANS(Executive Officer, Director)EUGENE A. BAUER(Executive Officer, Director)Christopher M. Griffith(Executive Officer, Promoter)Luis C. Pena(Executive Officer, Promoter)Thomas G. Wiggans(Executive Officer, Director, Promoter)Eugene A. Bauer(Executive Officer, Director, Promoter)
Co-investorsBay City CapitalCanaan PartnersForesite CapitalNew Enterprise Associates (NEA)Fidelity InvestmentsQiming Healthcare+1 more
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Executive Officer, Director)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCMission Bay CapitalMission BiocapitalOlive Tree CapitalSR One Capital ManagementTaiho Ventures, LLC+1 more
Co-investorsCanaan Partners
BiotechAnn Arbor, US
Antonio M. Gotto, Jr.(Director)Tim M. Mayleben(Executive Officer, Director)Gilbert S. Omenn(Director)Daniel Janney(Director)Dov A. Goldstein(Director)Roger S. Newton(Director)
Co-investorsAlta PartnersArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan PartnersLongitude Capital+2 more
Archimica is a contract manufacturer of active pharmaceutical ingredients (APIs), GMP building blocks and reagents, offering process development and production from clinical to large commercial scale for innovative and generic pharmaceutical companies.
Advanced ManufacturingBiotechHealthtechLodi, IT
F2G is a biotechnology company developing novel antifungal therapies to treat rare, life-threatening fungal infections in defined patient populations.
BiotechHealthtech
Co-investorsAdvent Life SciencesAMR Action FundAstellas Venture Management LLCBrace PharmaSofinnova PartnersSunstone Capital+3 more
Forge Biologics is a US-based gene therapy CDMO (contract development and manufacturing organization) offering AAV manufacturing services, technologies, and infrastructure.
Advanced ManufacturingBiotechHealthtechMedical DevicesGrove City, US
Timothy J. Miller(Executive Officer, Director)
BoardChris Garabedian(Director)Molly McCartin(Director)in
Co-investorsDrive CapitalRA Capital
Co-investorsAvoro Capital Advisors
Co-investorsOak Investment Partners
GondolaBio is a clinical-stage biopharmaceutical company developing therapeutics for patients with genetic diseases, with a lead oral small-molecule program (PORT-77) targeting erythropoietic protoporphyria and X-linked protoporphyria.
BiotechHealthtech
Co-investorsFrazier Life SciencesPatient Square Capital
IMBRUVICA is a prescription cancer medication (available as capsules, tablets, and oral suspension) used to treat B-cell malignancies such as CLL/SLL and Waldenström's macroglobulinemia, as well as chronic graft-versus-host disease in adults and children.
BiotechHealthtech
Co-investorsAdvent Life SciencesNew Enterprise Associates (NEA)Prospect Venture Partners
Intercept Pharmaceuticals is a biopharmaceutical company developing medicines for rare and serious liver diseases, with research centered on Farnesoid X Receptor (FXR) biology for conditions such as severe alcohol-associated hepatitis.
BiotechMedical Devices
Co-investorsBioBritRidgeback CapitalSamsara BioCapital
Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.
Co-investorsARCH Venture PartnersProspect Venture PartnersSchooner CapitalALTITUDE LIFE SCIENCE VENTURESFoley VenturesInvus
Lombard Medical is a medical device company providing solutions for the treatment of vascular disease, serving clinicians and patients.
HealthtechMedical Devices
Co-investorsCamden Partners
BiotechStamford, US
Joshua H. Bilenker(Executive Officer, Director)
BoardDov Goldstein(Director)James Barrett(Director)David Bonita(Director)Steven Elms(Director)Avi Naider(Director)
Co-investorsNew Enterprise Associates (NEA)
Lite Strategy, Inc.
BiotechCrypto & Web3FintechHealthtechSan Diego, US
David M. Urso(Executive Officer)Daniel P. Gold(Executive Officer, Director)Brian G. Drazba(Executive Officer)Mr. File(Chief Executive Officer & Board Member (former CFO))Kevan E. Clemens(Director)Thomas C. Reynolds(Director)
Co-investors3B Future Health FundGSRNew Enterprise Associates (NEA)Vivo Capital
Mindful Health Solutions is a psychiatric care provider offering interventional treatments for treatment-resistant depression, mood, and anxiety disorders, including Transcranial Magnetic Stimulation (TMS), SPRAVATO (esketamine), ketamine infusion therapy, and medication management.
Digital HealthHealthtechMental Health
miraDry offers an FDA-cleared medical procedure that uses thermal energy to permanently destroy underarm sweat glands, odor glands, and hair follicles, administered by trained healthcare practitioners.
HealthtechMedical DevicesWellness & Fitness
Co-investors1315 CapitalCross Creek Advisors
Medical Knowledge Group (MKG) is a commercialization partner for biopharma companies, offering data solutions, therapeutic expertise, and strategic advisory across a brand's product lifecycle.
Data & InfrastructureHealthtechMarketing Tech
Co-investorsEcoR1 CapitalLongitude Capital
The page is a Vietnamese-language sports streaming site (90Phut TV / 90Phutr.tv, also called Vaoroi TV) offering free live football streaming links, match schedules, standings, results, news, and betting odds.
Media & EntertainmentSports TechHà Nội, VN
Co-investorsM VenturesNew Enterprise Associates (NEA)Sofinnova PartnersSofinnova Ventures
BiotechMenlo Park, US
Ervin Epstein(Executive Officer, Director)Jean Tang(Director)Mark de Souza(Executive Officer)
BoardKatrin Andreasson(Director)
Co-investorsEcoR1 Capital
Pharmaron is a life science contract research and manufacturing service provider covering drug discovery, preclinical and clinical development, and commercialization.
BiotechHealthtechMedical Devices
Co-investorsDCM VenturesScientia VenturesDCMLegend Capital
Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications.
BiotechHealthtechSan Diego, US
Eric Ostertag(Executive Officer, Director)Mark Gergen(Executive Officer, Director)
BoardAdrian Howd(Director)David Hirsch(Director)
Co-investorsLongitude CapitalRapha Capital Management, LLCVivo Capital
HealthtechBelmont, US
S. Arieh Zak(Executive Officer)Barry Cheskin(Executive Officer, Director)Drew Schiff(Director)Michael Carusi(Director)Lou Bock(Director)George Green(Executive Officer)
Co-investorsArcher Capital GroupArcher Venture CapitalLightstone Ventures
Prolacta Bioscience manufactures 100% human milk-based nutritional products and fortifiers for premature and critically ill infants in hospital neonatal intensive care units.
BiotechHealthtechMedical DevicesCity Of Industry, US
Scott Elster(Executive Officer, Director)John M. Shields(Executive Officer)
BoardFrank Foster(Director)Martin Sutter(Director)David Brailer(Director)Dan Janney(Director)
Co-investorsEssex Woodlands Healthcare PartnersFrontier Venture CapitalPROOFAlta Partners
Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders.
BiotechHealthtechMental HealthMilwaukee, US
David Baker, PhD(Director)Daniel Lawton(Executive Officer, Director)Tom Beck(Executive Officer, Director)Chad Beyer(Executive Officer)Chad E Beyer, PhD(Executive Officer, Director)
BoardKlaus Veitinger(Executive Officer, Director)in
Co-investorsF-Prime CapitalOrbiMed
Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.
ConsumerMedia & EntertainmentSports Tech
Co-investorsNew Enterprise Associates (NEA)AbingworthLundbeckfonden VenturesPappas CapitalRiverVest Venture Partners
Roka Bio develops molecular pathogen detection assays that target ribosomal RNA (rRNA) for food pathogen testing.
BiotechFoodTechWarren, US
Lars Boesgaard(Executive Officer)Paul G. Thomas(Executive Officer, Director)
BoardJim Barret, PhD(Director)Fred Cohen(Director)Jonathan Silverstein(Director)David McGirr(Director)
Sorrento Therapeutics is a biotechnology and life sciences company that develops therapeutics and technologies through in-house programs, acquisitions, and mergers.
BiotechDeep TechLongevity
Henry Ji(Chairman, President and CEO)Scott Schaus(Chief Technology Officer)
Co-investorsCanaan Partners
SkinMedica sells skincare products such as facial serums and cleansers targeting concerns like fine lines, wrinkles, and acne.
BiotechConsumerDirect to ConsumerWellness & FitnessCarlsbad, US
Theodore Schwarz(Executive Officer)George Jenkins(Director)Andrew N. Schiff, M.D.(Director)Brian Dovey(Director)David F. Hale(Director)Theodore Ebel(Executive Officer)
Menlo Park, US
Duke Rohlen(Chief Executive Officer)
BoardCamille Samuels(Director)Anthony Natale(Director)inReed Gaither(Director)Aftab Kherani(Director)Ron Kuppersmith(Director)
Co-investorsAPERTURE Venture PartnersCorrelation VenturesVenrockHealthQuest CapitalVenrock AssociatesWestern Technology Investment
Co-investorsAvoro Capital AdvisorsBioBritDelos CapitalEcoR1 Capital
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Co-investorsARCH Venture PartnersQuan CapitalFlagship VenturesREDMILE
HealthtechLexington, US
Michael Cima, Ph.D.(Director)Rahul Dhanda(Senior Vice President, Corporate Development)John McDonough(Chief Executive Officer)Tom Lowery, Ph.D.(Chief Scientific Officer)Michael Gibbs, Esq.(Vice President and General Counsel)Joanne Spadoro, Ph.D.(Chief Operating Officer)
Co-investorsLongitude Capital
Merck is a pharmaceutical company focused on developing medicines and vaccines for patients globally, guided by a science-led innovation strategy.
BiotechHealthtechMedical DevicesRahway, US
Co-investorsAtlas VentureHM Venture PartnersSanderling VenturesSPRINGROCK VENTURESThe Column Group
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)The Column Group
Tria Beauty makes at-home laser devices for consumers, including the Tria 4X hair removal laser and the FRX skin rejuvenating fractional laser for reducing fine lines and improving pigmentation.
ConsumerDirect to ConsumerHealthtechWellness & FitnessDublin, US
TOBIN C. ISLAND(Executive Officer)KEVIN J. APPELBAUM(Executive Officer, Director)DEREK YUNG(Executive Officer)DANIKA HARRISON(Executive Officer)JIYOUNG CHOI(Executive Officer)CHARLES BRACHER(Director)
Co-investorsBay City CapitalIncubic Management LLC
UroGen is a biopharmaceutical company developing and commercializing treatments for urological cancers, including FDA-approved therapies such as JELMYTO and ZUSDURI built on its RTGel technology.
BiotechHealthtechPrinceton, US
Elizabeth Barrett(Executive Officer, Director)Mark Schoenberg, M.D.(Executive Officer)Jason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Don Kim(Executive Officer)
Co-investorsMonograph Capital PartnersPontifax Venture Capital
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)Peter Spargo(Executive Officer)Patrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Co-investorsAccess BiotechnologyAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)Sofinnova Partners+4 more
Co-investorsSofinnova Ventures
ViewRay develops MRIdian A3i, an MRI-guided radiation therapy system that uses diagnostic-quality MRI imaging for real-time tissue tracking and automated beam control during cancer treatment.
HardwareHealthtechMedical DevicesOakwood Village, US
James F. Dempsey(Executive Officer, Director)James Dempsey(Secretary of the Issuer.)David Chandler(Mr. Chandler is the Chief Financial Officer of the Issuer.)Chris A. Raanes(Executive Officer, Director)Michael Brandt(Executive Officer)D. David Chandler(Executive Officer)
Co-investorsF-Prime CapitalOrbiMed
Viracta Therapeutics was a precision oncology company.
BiotechHealthtechCardiff, US
Co-investorsLatterell Venture Partners
VIVUS is a global pharmaceutical company that develops and commercializes therapies for patients with serious medical conditions and life-limiting diseases.
BiotechHealthtech
Co-investorsFrazier Life Sciences
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)Cherry Thomas(Executive Officer)Kumar Srinivasan(Executive Officer, Director)Keith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Co-investorsAlpha Wave GlobalBioGenerator VenturesRiverVest Venture PartnersAbingworthFidelity InvestmentsIntermediate Capital Group+1 more
BiotechFremont, US
Peter Daddona(Executive Officer, Director)Winnie Tso(Executive Officer)Nandan Oza(Executive Officer)Vikram Lamba(Executive Officer, Director)Christopher Krueger(Executive Officer)
BoardM. James Barrett(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 16
IPOs and acquisitions across the tracked portfolioMonte Rosa TherapeuticsNASDAQ: GLUELensarNASDAQ: LNSRMarker TherapeuticsNASDAQ: MRKRAclaris TherapeuticsNASDAQ: ACRSAdmabiologicsNASDAQ: ADMABicara TherapeuticsNASDAQ: BCAXBiomea FusionNASDAQ: BMEACompass PathwaysNASDAQ: CMPSHarmony BiosciencesNASDAQ: HRMYJohnson & JohnsonNYSE: JNJNuvation BioNYSE: NUVBProtagonist TherapeuticsNASDAQ: PTGXScholar RockNASDAQ: SRRKSpruce BiosciencesNASDAQ: SPRBSpyre TherapeuticsNASDAQ: SYREIntercept Pharmaceuticalsacq. by Alfasigma
Portfolio news
latest coverage across their companiesNuvation Bio · aromatherapynaturals.com · Aug 22, 2026
Cidara Therapeutics · tradingkey.com · Aug 20, 2026
Urogen · investing.com · Aug 19, 2026
Arcus Biosciences · pluang.com · Aug 19, 2026
Spyre Therapeutics · investing.com · Aug 18, 2026
Spruce Biosciences · stocktitan.net · Aug 14, 2026
Forge Biologics · biopharminternational.com · Aug 12, 2026
Fund performance · per public LP disclosures · 5
as of Sep 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Aisling Capital IV, L.P.LPs: Pennsylvania Public School Employees' Retirement System, Andrew W. Mellon Foundation | 2015 | — | 11.6% | 1.74x | 0.68x |
| Aisling Capital IIILPs: New York City Police Pension Fund | 2008 | — | 26.4% | 2.38x | 2.38x |
| Aisling Capital III, L.P.LPs: California Public Employees' Retirement System, Pennsylvania Public School Employees' Retirement System, Empire State Development – New York Ventures +6 more | 2008 | — | 26.5% | 2.38x | 2.38x |
| Aisling Capital IILPs: New York City Police Pension Fund | 2006 | — | 0.6% | 1.04x | 1.04x |
| Aisling Capital II, L.P.LPs: California Public Employees' Retirement System, Pennsylvania Public School Employees' Retirement System, Empire State Development – New York Ventures +5 more | 2005 | — | 0.9% | 1.06x | 0.99x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has Aisling Capital made?
- Aisling Capital has 119 tracked investments, 4 of which have exited via acquisition or IPO, including 3 dated in the last 24 months.
- What stage does Aisling Capital invest at?
- Aisling Capital invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Aisling Capital focus on?
- Aisling Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Aisling Capital located?
- Aisling Capital is headquartered in New York, US.
- Who does Aisling Capital co-invest with?
- Aisling Capital most often shares deals with New Enterprise Associates (NEA), EcoR1 Capital, Canaan Partners, among 119 tracked co-investors.
Co-investors · 28
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.
Alta Partners is a venture capital firm focused on the healthcare and life sciences sector, backing entrepreneurs building companies across biotechnology, therapeutics, and healthcare innovation.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
Domain Associates is a venture capital firm founded in 1985 that invests in life sciences companies. The firm operates as a limited liability company.
Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.
▶16 more co-investors
Polaris PartnersDrive CapitalVersant VenturesSV Health InvestorsHealthQuest CapitalHBM PartnersUS Venture PartnersGeneral AtlanticFlare Capital PartnersJohnson & Johnson Innovation – JJDCFlagship PioneeringMorgenthalerFrazier Healthcare PartnersACORN BIOVENTURESDe Novo VenturesJumpstart Foundry
Firms observed investing alongside Aisling Capital, from public investor directories. Shared companies are the overlap with Aisling Capital's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.